

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Building 31, Conference Rooms C, D&E, and F&G, 31 Center Drive, Bethesda, MD 20892.

*Contact Person:* Karl F. Malik, Ph.D., Director Division of Extramural Activities, National Institutes of Diabetes and Digestive and Kidney Diseases, 6707 Democracy Boulevard, Room 7329, MSC 5452, Bethesda, MD 20892, (301) 594-4757 malikk@nidk.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: [www.nidk.nih.gov/fund/divisions/DEA/Council/coundesc.htm](http://www.nidk.nih.gov/fund/divisions/DEA/Council/coundesc.htm), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: December 21, 2021.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-28097 Filed 12-27-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute on Aging; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which

would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Aging Special Emphasis Panel; Age-related metabolites, mitochondrial and synaptic degeneration & rescue in Aging and Alzheimer's disease.

*Date:* March 23, 2022.

*Time:* 11:30 a.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Video Meeting).

*Contact Person:* Anita H. Undale, MD, Ph.D., Scientific Review Officer, Scientific Review Branch, National Institute on Aging, National Institutes of Health, Gateway Building, Suite 2W200, 7201 Wisconsin Avenue, Bethesda, MD 20892, 301-827-7428, [anita.undale@nih.gov](mailto:anita.undale@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: December 21, 2021.

**Miguelina Perez,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-28091 Filed 12-27-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of Exclusive Patent License: "Griffithsin Compositions for Treatment and Prevention of Anti-Viral Infections"

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to University of Louisville Research Foundation, ("ULRF") in its rights to the inventions and patents listed in the Supplementary Information section of this notice. ULRF is a Kentucky 501(c)3 non-profit corporation that is the agent of the University of Louisville ("UofL") for licensing intellectual property owned and controlled by ULRF on behalf of UofL. **DATES:** Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center January 12, 2022 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be

directed to: Taryn Dick, Ph.D., MBA, Licensing and Patenting Manager at Telephone: (301) 631-3007 or Email: [taryn.dick@nih.gov](mailto:taryn.dick@nih.gov).

**SUPPLEMENTARY INFORMATION:** The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement to ULRF: U.S. Provisional Patent Application No. 63/026,375 entitled "Compositions and Methods for Prevention of Coronavirus Infection," (HHS Ref. No. E-029-2022-0-US-01), filed 18 May 2020; PCT Application No. PCT/US2021/033009 entitled "Compositions and Methods for Prevention of Coronavirus Infection," (HHS Ref. No. E-029-2022-1-PCT-02), filed May 18, 2021; U.S. Provisional Patent Application No. 62/898,383 entitled "Anti-Viral Compositions and Methods of Making and Using," (HHS Ref. No. E-030-2022-0-US-01), filed September 10, 2019; and PCT Application No. PCT/US2020/050200, entitled "Anti-Viral Compositions and Methods of Making and Using" (HHS Ref. No. E-030-2022-0-PCT-02), filed September 10, 2020.

PCT/US2021/033009 described above claims priority to the U.S. Provisional Patent Application No. 63/026,375 described above, as well as a second U.S. Provisional Patent Application No. 63/070,375 entitled "Q-Griffithsin Nasal Spray," (HHS Ref. No. E-029-2022-1-US-01), filed on August 26, 2020. The Government of the United States is not a co-owner on this second U.S. Provisional Patent Application, and it is therefore, excluded from the proposed exclusive grant from NCI to ULRF.

With respect to the inventions described and claimed in the patent applications 62/026,375 (E-029-2022-0-US-01) and PCT/US2021/033009 (E-029-2022-1-PCT-02) each of the inventors has assigned their rights to their respective employers or an entity which manages the intellectual property for their employer (The Government of the United States of America, the University of Louisville Research Foundation, Inc. or the University of Pittsburgh). With respect to the inventions described and claimed in the patent applications 62/898,383 (E-030-2022-0-US-01) and PCT/US2021/050200 (E-030-2022-0-PCT-01) each of the inventors has assigned their rights to their respective employers or an entity which manages the intellectual property for their employer (The Government of the United States or the University of Louisville Research Foundation, Inc.). The prospective